G.T. Ferguson, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine,一种PDE3和PDE4的双重抑制剂,无论背景药物使用如何,都可以降低恶化的风险:一项3期试验ENHANCE-2的亚组分析","authors":"G.T. Ferguson, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":332705,"journal":{"name":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","volume":"79 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial\",\"authors\":\"G.T. Ferguson, T. Rheault, T. Bengtsson, K. Rickard\",\"doi\":\"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":332705,\"journal\":{\"name\":\"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD\",\"volume\":\"79 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C40. CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4999","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial